UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency

Blood, 2012-05, Vol.119 (22), p.5111-5117

2012

Volltextzugriff (PDF)

A New Statistical Test Based on the WR for Detecting Offsets in GPS Experiment

Earth and space science (Hoboken, N.J.), 2020-08, Vol.7 (8), p.n/a

2020

Volltextzugriff (PDF)

Dasiglucagon Effects on QTc in Healthy Volunteers: A Randomized, Placebo-Controlled, Dose-Escalation, Double-Blind Study

Current therapeutic research, 2022-01, Vol.96, p.100668-100668, Article 100668

2022

Volltextzugriff (PDF)

The WHO classification of MDS does make a difference

Blood, 2004-05, Vol.103 (9), p.3265-3270

2004

Volltextzugriff (PDF)

Defining the Ideal Injection Techniques When Using 5-mm Needles in Children and Adults

Diabetes care, 2010-09, Vol.33 (9), p.1940-1944

2010

Volltextzugriff (PDF)

Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors

Blood, 2003-02, Vol.101 (3), p.1080-1086

2003

Volltextzugriff (PDF)

Dasiglucagon: A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia Results of Phase 3 Randomized Double-Blind Clinical Trial

Diabetes care, 2021-06, Vol.44 (6), p.1361-1367

2021

Volltextzugriff (PDF)

Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial

Diabetes care, 2021-06, Vol.44 (6), p.1361

2021

Volltextzugriff (PDF)

Antiapoptotic Role of Growth Factors in the Myelodysplastic Syndromes: Concordance Between In vitro and In vivo Observations

Clinical cancer research, 2005-09, Vol.11 (17), p.6291-6299

2005

Volltextzugriff (PDF)

Ready-to-use Dasiglucagon Injection as a Rapid and Effective Treatment for Severe Hypoglycemia

Metabolism, clinical and experimental, 2021-03, Vol.116, p.154506, Article 154506

2021

Volltextzugriff (PDF)

Dasiglucagon—A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial

Diabetes care, 2021-04, Vol.44 (6), p.1361-1367

2021

Volltextzugriff (PDF)

Dasiglucagon, a next‐generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double‐blind trial

Diabetes, obesity & metabolism, 2021-10, Vol.23 (10), p.2329-2335

2021

Volltextzugriff (PDF)

286-OR: Phase 3 Results for Dasiglucagon as a Fast and Effective Treatment for Severe Hypoglycemia

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission

The New England journal of medicine, 2010-09, Vol.363 (11), p.1025-1037

2010

Volltextzugriff (PDF)

137-OR: Dasiglucagon Ready-to-Use Autoinjector Is More Reliably and Quickly Administered than Glucagon Emergency Kit (GEK)

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

356-P: Population Pharmacokinetic Modeling of Dasiglucagon in Subjects with Type 1 Diabetes Mellitus

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Dasiglucagon, a next‐generation ready‐to‐use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial

Pediatric diabetes, 2021-08, Vol.22 (5), p.734-741

2021

Volltextzugriff (PDF)

The Next-generation Glucagon Analog Dasiglucagon Consistently Achieves Rapid Recovery From Hypoglycemia Across Subgroups

Metabolism, clinical and experimental, 2022-03, Vol.128, p.155043, Article 155043

2022

Volltextzugriff (PDF)

180-OR: Dasiglucagon as a Fast and Effective Treatment for Severe Hypoglycemia in Children with Diabetes

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

1053-P: Dasiglucagon Hypopal Autoinjector as a Fast and Effective Treatment for Severe Hypoglycemia: Results of a Phase 3 Trial

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

Dasiglucagon, a Ready-To-Use Glucagon Analog, For Rapid And Effective Treatment of Severe Hypoglycemia: a Phase 3, Randomized Controlled Trial in Children With Type 1 Diabetes

Metabolism, clinical and experimental, 2021-03, Vol.116, p.154507, Article 154507

2021

Volltextzugriff (PDF)

An alternative method for non-negative estimation of variance components

Journal of geodesy, 2014-05, Vol.88 (5), p.427-439

2014

Volltextzugriff (PDF)

344-P: Integrated Safety Analysis of Dasiglucagon for Treatment of Severe Hypoglycemia

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

345-P: The Next Generation Glucagon Analog Dasiglucagon Consistently Achieves Rapid Recovery from Hypoglycemia across Subgroups

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

346-P: Predicting True Time to Recovery from Insulin-Induced Hypoglycemia with Dasiglucagon

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(15)
Humans
(13)
Life Sciences & Biomedicine
(13)
Hypoglycemia
(10)
Biological And Medical Sciences
(9)
Diabetes
(9)
Diabetes Mellitus
(9)
Glucagon
(9)
Medical Sciences
(9)
Medicin Och Hälsovetenskap
(9)
Adult
(7)
Hematologic And Hematopoietic Diseases
(7)
Female
(6)
Insulin
(6)
Middle Aged
(6)
Nausea
(6)
Vomiting
(6)
Aged
(5)
Granulocyte Colony-Stimulating Factor - Pharmacology
(5)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency

A New Statistical Test Based on the WR for Detecting Offsets in GPS Experiment

Dasiglucagon Effects on QTc in Healthy Volunteers: A Randomized, Placebo-Controlled, Dose-Escalation, Double-Blind Study

The WHO classification of MDS does make a difference

Defining the Ideal Injection Techniques When Using 5-mm Needles in Children and Adults

Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors

Dasiglucagon: A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia Results of Phase 3 Randomized Double-Blind Clinical Trial

Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial

Antiapoptotic Role of Growth Factors in the Myelodysplastic Syndromes: Concordance Between In vitro and In vivo Observations

Ready-to-use Dasiglucagon Injection as a Rapid and Effective Treatment for Severe Hypoglycemia

Dasiglucagon—A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial

Dasiglucagon, a next‐generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double‐blind trial

286-OR: Phase 3 Results for Dasiglucagon as a Fast and Effective Treatment for Severe Hypoglycemia

Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission

137-OR: Dasiglucagon Ready-to-Use Autoinjector Is More Reliably and Quickly Administered than Glucagon Emergency Kit (GEK)

356-P: Population Pharmacokinetic Modeling of Dasiglucagon in Subjects with Type 1 Diabetes Mellitus

Dasiglucagon, a next‐generation ready‐to‐use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial

The Next-generation Glucagon Analog Dasiglucagon Consistently Achieves Rapid Recovery From Hypoglycemia Across Subgroups

180-OR: Dasiglucagon as a Fast and Effective Treatment for Severe Hypoglycemia in Children with Diabetes

1053-P: Dasiglucagon Hypopal Autoinjector as a Fast and Effective Treatment for Severe Hypoglycemia: Results of a Phase 3 Trial

Dasiglucagon, a Ready-To-Use Glucagon Analog, For Rapid And Effective Treatment of Severe Hypoglycemia: a Phase 3, Randomized Controlled Trial in Children With Type 1 Diabetes

An alternative method for non-negative estimation of variance components

344-P: Integrated Safety Analysis of Dasiglucagon for Treatment of Severe Hypoglycemia

345-P: The Next Generation Glucagon Analog Dasiglucagon Consistently Achieves Rapid Recovery from Hypoglycemia across Subgroups

346-P: Predicting True Time to Recovery from Insulin-Induced Hypoglycemia with Dasiglucagon

Suchergebnisse filtern